Uncategorized - ImVitro

Save time and energy with EMBRYOLY’s digital and secure frozen embryo consents

About us & our product ImVitro’s SaaS platform EMBRYOLY is an AI-powered software. EMBRYOLY’s core feature provides a ranking based on the embryo’s morphokinetics as well as a subsequent transfer priority recommendation personalized to the patient for increased accuracy. See our product page for more information! The challenge In many cases,…

Estimate the realistic value-add of EMBRYOLY on your clinic’s global first cycle pregnancy rate

About us & our product ImVitro’s SaaS platform EMBRYOLY is an AI-powered software. EMBRYOLY’s core feature provides a ranking based on the embryo’s morphokinetics as well as a subsequent transfer priority recommendation personalized to the patient for increased accuracy. See our product page for more information! The challenge Ranking embryos is…

How will EMBRYOLY positively impact your clinic’s productivity?

Answer these questions to download a personalized and concise report about how EMBRYOLY will positively impact your clinic’s productivity. 1. All questions are compulsory. If unsure, we suggest some values as per our customer’s feedback and the literature that you could use as rough estimates. If the embryologist is in…

Reduce blastocyst grading variability with EMBRYOLY

About us & our product ImVitro’s SaaS platform EMBRYOLY is an AI-powered software. EMBRYOLY’s core feature provides a ranking based on the embryo’s morphokinetics as well as a subsequent transfer priority recommendation personalized to the patient for increased accuracy. See our product page for more information! The challenge While evaluating the…

Not a lost cause for EMBRYOLY when only poor-quality embryos are available

About us & our product ImVitro’s SaaS platform EMBRYOLY is an AI-powered software. EMBRYOLY’s core feature provides a ranking based on the embryo’s morphokinetics as well as a subsequent transfer priority recommendation personalized to the patient for increased accuracy. See our product page for more information! The challenge Embryo morphokinetics is…

Accelerate embryo evaluation and anticipate pregnancy outcomes better with EMBRYOLY

About us & our product ImVitro’s SaaS platform EMBRYOLY is an AI-powered software. EMBRYOLY’s core feature provides a ranking based on the embryo’s morphokinetics as well as a subsequent transfer priority recommendation personalized to the patient for increased accuracy. See our product page for more information! The challenge Embryo evaluation is…

Deprioritize embryos at risk of being aneuploid with EMBRYOLY

About us & our product ImVitro’s SaaS platform EMBRYOLY is an AI-powered software. EMBRYOLY’s core feature provides a ranking based on the embryo’s morphokinetics as well as a subsequent transfer priority recommendation personalized to the patient for increased accuracy. See our product page for more information! The challenge Many aneuploid embryos…

EMBRYOLY ranks any embryo across a network of clinics, no matter the patient or prognosis

About us & our product ImVitro’s SaaS platform EMBRYOLY is an AI-powered software. EMBRYOLY’s core feature provides a ranking based on the embryo’s morphokinetics as well as a subsequent transfer priority recommendation personalized to the patient for increased accuracy. See our product page for more information! The challenge Patients often go…

Embryoly is now connected to GERI® for deeper integration in IVF labs

Earlier in the year, we had connected our platform to the Embryoscope® and Embryoscope+® (Vitrolife). We are now thrilled to announce that we are also connected to the GERI® (Genea BiomedX), another major player amongst time-lapse microscopes! One more to go…. Stay tuned!

ImVitro at the AWS Summit Paris

Our CEO and founder Alexandra Boussommier was the guest of the AWS Summit Paris alongside Dali Kilani, CTO of Lifen to talk about conformity and regulatory requirements with AWS cloud computing. Both founders explore how their companies are using cloud computing technology in healthcare and advises other aspiring founders. For…

Alexandra Boussommier joins Adastra ventures’s bootcamp!

Our CEO and founder Alexandra Boussommier was accepted into the adastra.ventures founder bootcamp “Get to Even”! We are excited for Alexandra’s participation and grateful for Ad Astra‘s support of female founders and leaders.

ImVitro is accepted into digital health incubator Bpifrance

It is a great honor to announce that ImVitro is part of the the digital health incubator led by Bpifrance and Fondation Université Paris, alongside the startups Ma Clinique Digitale, MedInBox, Mobaspace, MyPL and Tricky. Thanks to both for their support and trust!

ImVitro, a key actor of fertility tech according to Cherry Ventures

Women’s health and infertility is at the heart of attention in Europe and investors are aware of it. It is wonderful to see ImVitro being mentioned by Cherry Ventures as one of the key actors in Europe that works to improve IVF outcomes and reduce the time to pregnancy. More…

ImVitro & INOVIE

Cela fait plus de 2 ans que nous avons entamé notre projet, et les centres d’INOVIE fertilité ont été parmi les premiers à y croire. Ils sont donc aujourd’hui parmi les premiers à nous faire des retours sur notre interface qui commence à être mise à disposition de nos partenaires…

ImVitro at BPIFrance BIG event

Today, our CEO Alexandra Boussommier is invited to talk with a great panel of researchers and entrepreneurs in front of students & young researchers at Accorhotels Arena for the yearly event organized by BPIFRANCE “La Deeptech fait son BIG !”. The session mediated by Antoine petit (PDG CNRS) is called…

ImVitro, a “Femtech startups to watch in Europe, according to top VCs”

Although ImVitro helps patient of all genders, and is therefore not just about FemTech, it is great to see ImVitro being mentioned in Sifted as one of the Europeans start-ups in fem-tech to watch out for! More info here: https://sifted.eu/articles/femtech-startups-to-watch-according-to-vcs/

TechnologyNetworks talks about ImVitro

To learn more about IVF and how artificial intelligence could help to address some of the challenges associated with the technique, check out the interview of our CEO Alexandra Boussommier about ImVitro published on TechnologyNetworks. It is great to see our work talked on such a well known media.

Is IVF only a woman’s issue?

Molly Heath originally contacted ImVitro in the context of EF’s Focus on FemTech series. Our discussion was a great opportunity to reflect on the fact that IVF is actually not just a woman’s issue: enjoy the read!

ImVitro on BFM Business

Last week, ImVitro was invited on “Check up Santé” on BFM Business as one of 3 health startups (along with Posos and Healthy Mind) that spinned off Station F to showcase how important incubators such as Station F can be in a startup journey, along with its many accelerator programs…

ImVitro @ Women in Science

Women in Science aim is to promote the role of women in data science, who are underrepresented in this field as well as other science related fields, both in research, industry and start-ups. Alexandra was invited to discuss ImVitro and her career path during the event WISE II (Women in…

ImVitro on Chet’s Morning Linkedin Live Breakfast podcast

Chetan Halaui interviews Alex on his breakfast show to learn more about her journey as a founder and what ImVitro is currently working on. Thank you Chet for this opportunity! Click here to see the interview

Building Something with Alexandra Boussommier-Calleja: ImVitro

In November 2019, ImVitro was selected as one of the future 40 promising start ups at Station F. In this interview, Station F followed up 6 months later with the company, giving Alexandra the chance to re-explain the vision and mission of the company. Thanks again to Station F for…

From academia to founding a start up

Alexandra gives a talk for the Paris Biotech group about the use of AI applied to IVF and more generally about her transition from academia to founding a company. Thanks again to Yulia Dembitskaya for organizing this!

ImVitro receives the BPI Deep Tech Emergence grant

ImVitro receives the French Tech Emergence grant 90K Euros grant from the BPI aimed at supporting innovative companies focused on R&D Thanks to BPI for their support!

ImVitro on CNEWS

For our francophone readers, check out the article about ImVitro today published on the newspaper Cnews here.

ImVitro selected as one of the Future40 by StationF

Today, ImVitro was selected as one of the future 40 promising start ups at Station F. To learn more about us, check out the pitch of our CEO Alexandra Boussommier here. Thanks to Station F for this opportunity!

Introducing 6 founders, 6 months into their start-up journey

Take a look at the very beginning of ImVitro’s journey (and that of other EF startups) as told by the accelerator Entrepreneur First!